HAYWARD, Calif., May 3 /PRNewswire/ -- Metabolex, Inc., a biotechnology company dedicated to the discovery and development of novel therapeutics for diabetes and related metabolic disorders, announced today that it has hired Bonnie Charpentier as vice president, regulatory affairs. In that position, Charpentier will oversee all aspects of regulatory compliance for the company’s three clinical-stage compounds and direct the regulatory process of advancing preclinical candidates in human testing.
“We have both an exciting late-stage clinical compound and a broad pipeline of early clinical and preclinical compounds, and Bonnie will be vital in ensuring that these programs run smoothly,” said President and Chief Executive Officer Harold Van Wart, Ph.D. “Bonnie has more than 25 years of experience in industry, making her the best possible choice to oversee a regulatory affairs function that will only grow in importance as our lead compound, MBX-102, completes Phase 2/3 testing.”
The company’s lead insulin sensitizer, MBX-102, is now in a 400-patient Phase 2/3 study in patients with type 2 diabetes who use insulin. Metabolex entered into a strategic alliance with Ortho-McNeil, Inc. in 2006, giving Ortho-McNeil an exclusive license for worldwide development and commercialization of MBX-102 and MBX-2044, a follow-on insulin sensitizer. Metabolex is conducting the Phase 2/3 trial of MBX-102 and a Phase 2a trial of MBX-2044.
Charpentier joins Metabolex after five years as vice president, regulatory and compliance, at Genitope Corporation. Prior to serving there, Charpentier spent a decade at Syntex Corporation, which was purchased by Roche Holding in 1995. She left Roche Global Development in 2001 as vice president and regulatory site head. Charpentier serves on the Board of Directors of the American Chemical Society and holds a Ph.D. in biology from the University of Houston.
About Metabolex
Metabolex is a privately held biotechnology company dedicated to the discovery and development of novel therapeutics to transform the treatment of diabetes and related metabolic disorders. Metabolex has drawn on its deep understanding of diabetes to create the largest database of genes involved in diabetes and to build a rich pipeline of product candidates and drug discovery targets. The company has three clinical-stage compounds: MBX-102, in Phase 2/3 testing; MBX-2044, in Phase 2a; and MBX-8025, being studied in dyslipidemia, which has completed Phase 1 studies. Ortho-McNeil, Inc. has the exclusive right to develop and commercialize MBX-102 and MBX-2044.
For additional information about Metabolex and its development pipeline, visit www.metabolex.com
Metabolex, Inc.
CONTACT: Mark Bagnall of Metabolex, +1-510-293-8800, ormbagnall@metabolex.com; or Brian Reid of WeissComm Partners,+1-703-402-3626, or breid@weisscommpartners.com, for Metabolex
Web site: http://www.metabolex.com//
